Across TCGA pan-cancer cohorts, MIR517A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR517A data layer compared with 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR517A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR517A expression acts as an unfavorable survival marker.

LIHC and LUAD are the cancer types where MIR517A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR517A tumor-vs-normal RNA expression · all MIR517A data types